• BIA Blog

CEO Update | 30 January 2023

The end of January is always incredibly busy at the BIA, with our first Board meeting of the year welcoming newly elected members, the publication of our annual report into the financing of the sector and of course our Gala Dinner which was a great evening last week. Read more on R&D tax credit campaign at centre of finance work, the Chancellors’ growth speech and more.

CEO Update | 23 January 2023

This week is one of the busiest in the BIA calendar as we host our much looked-forward-to Gala Dinner, get ready to publish last year's finance figures for the sector and gather our new Board for the first time in 2023. More on all this in next week’s Newscast. I look forward to seeing over 600 of you on Thursday night at the Brewery. Read on for AMR national action plan and how CGI blockbuster, Avatar, is in fact important life science work.

Real-world evidence: the panacea for rare diseases?

The publication of the National Institute for Health and Care Excellence’s real-world evidence framework in June 2022 has accelerated discussions about the role that real-world evidence can play in resolving gaps in knowledge and driving forward access to innovations for patients with rare diseases. Senior Policy and Public Affairs Executive, Joe Smale, reflects on a recent BIA-facilitated discussion on the potential of real-world evidence in rare diseases and the importance of patient involvement in future discussions.

How early-stage life sciences companies can improve the odds of attracting funding

The last decade has witnessed a boom in life science start-ups and that pace is set to continue as the search goes on to find improved treatments for diseases including Alzheimer’s and cancer. The science has been backed by record levels of funding, with investment into life sciences in the UK reaching a record £4.5 billion in 2021. Read this blog to learn what start-ups need to know about early-stage funding.

Annual Supporter Spotlight: RBW Consulting

This week, BIA is pleased to announce RBW Consulting as our newest Annual Supporter. RBW Consulting is a proudly B Corp certified life sciences recruitment and search consultancy with purpose, delivered through what they call Human Intelligence. Read this blog by Emma Thorp, Chief Commercial Officer to learn more!

CEO Update | 16 January 2023

It was great to see the UK out in force at the annual JPM conference in San Francisco last week, especially at the reception we hosted with the Government at the Marines' Memorial Club. With over 300 attendees, I know many of you found meeting BioNTech founder and CEO Uğur Şahin a highlight. It was great to learn that BioNTech is opening space in Cambridge, UK and marked their JPM week with the announcement of the acquisition of UK AI start-up InstaDeep in £562 million deal.

Harnessing the economic potential of UK life sciences

This week, the British Business Bank was pleased to announce that our commercial subsidiary British Patient Capital made its first investment from the Life Sciences Investment Programme into the SV Biotech Crossover Opportunities Fund (SV BCOF). Read this blog to learn more!

CEO Update | 9 January 2023

I write this week from San Francisco where the JPM conference is now well underway – with full participation from the UK ecosystem. Folk are already talking about  the announcement of BioNtech’s MoU with the UK Government to develop next generation cancer vaccines in partnership. Also demonstrating the UK’s capability in accelerated innovation is the news from RQ Bio and AstraZeneca that the first of RQ’s monoclonal antibodies to prevent COVID-19 in vulnerable patients, which originates from work of the BIA Antibody Taskforce, has entered clinical trials less than 12 months after discovery, with the start of AZ’s SUPERNOVA Phase I/III trial.

Stepping into leadership roles with UKRI's Future Leaders Fellowships

Meet Ioanna Mylonaki and Alice Ghidini of Sixfold Bioscience, both UKRI Future Leader Fellows. Read this Q&A blog, detailing their experience of transition from academia to leadership roles.

CEO Update | 19 December 2022

Reflections on 2022 and look forward to 2023. Our life science sector is continuing to deliver world-changing products and services at a pace and scale that will transform lives in the years to come. And whether the breakthrough highlighted be next-generation products for type 2 diabetes, novel malaria vaccines, new developments in mRNA vaccinology or cell and gene therapy for the early diagnosis of cancer, I see the UK innovation ecosystem engaged and involved in world-leading programmes.